The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Levin A, Neal B, Wheeler DC, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Jardine MJ, Smyth B.
Liao J, et al. Among authors: young t.
Diabetes Metab. 2022 Jul;48(4):101331. doi: 10.1016/j.diabet.2022.101331. Epub 2022 Feb 13.
Diabetes Metab. 2022.
PMID: 35172198
Clinical Trial.